LY4052031 — Investigational Agent
Antibody-Drug Conjugate · Phase 1 · Eli Lilly
Mechanism of Action
An FGFR3-directed antibody-drug conjugate that targets FGFR3 on urothelial and other tumors, delivering a cytotoxic payload independent of FGFR3 activating mutation status.
Investigational Indications
- Advanced/metastatic urothelial carcinoma
- FGFR3-expressing solid tumors